Navigation Links
GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
Date:12/1/2009

for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $18 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
2. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
3. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
4. GeoVax Labs Requests pre-IND Meeting With FDA
5. GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
6. GeoVax Labs, Inc. Provides Clinical Studies Update
7. GeoVax Labs, Inc. Announces Resignation of Director
8. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
9. GeoVax to Exhibit at the 2009 BIO International Convention
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... An increase of awareness related to benefits ... food nutrients, regulatory changes and concerns related to consumer ... for natural astaxanthin over the past few years. Producers ... capacities to satisfy the rising demand. , The ... (used in nutraceuticals, aqua feed, food and beverages and ...
(Date:3/25/2015)... MN (PRWEB) March 25, 2015 ... breakthrough in nanoparticle technology that will enable broader ... many other diseases with a simple breath screen. ... on the U.S. Food and Drug Administration (FDA) ... launch of the innovative Nanoparticle Biomarker Tagging device. ...
(Date:3/25/2015)... , March 25, 2015  18 piglets born ... intense research by scientists in the College of Agriculture ... represent a breakthrough in the field of genetic ... the Department of Animal & Avian Sciences (ANSC) and ... ANSC, successfully produced genome-edited pigs using a recently ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... BARCELONA, Spain , June 14 Data ... in Barcelona , highlights the impact of febrile ... patients. The IMPACT NHL study showed that unplanned hospitalisations, ... to suboptimal relative dose intensity (RDI) of chemotherapy were ...
... ... Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with ... be held October 4-5, 2010 in Philadelphia, Pennsylvania. , ... Minneapolis, MN (PRWEB) June 10, ...
... ... oldest buildings on earth and a “fascinatingly weird” ancient culture. , ... (PRWEB) June 11, 2010 -- U.S. nonprofit The ... a simple introduction to megalithic architects in Frequently Asked Question format. With content drawn ...
Cached Biology Technology:New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 2New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 3New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 4New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 5New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 6New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 7New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 8New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 9Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit 2New tool for exploring the ancient world. 2
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... army ants in the rainforests of Central and South America ... Remarkably, some ants use their bodies to plug potholes in ... surface so that prey can be delivered to the developing ... to the nest by a trail of forager traffic, along ...
... A noninvasive ultrasound procedure effectively shrinks uterine fibroids ... to the results of a multicenter clinical trial ... Radiology. Magnetic resonance-guided, focused ultrasound surgery (MRgFUS) allows ... surrounding tissue. , "This treatment immediately stops ...
... the DNA codes of over 40,000 women -- ... without the disease – has uncovered five common genetic ... , In a paper published online today in the ... the genome-wide association study report that these five genes ...
Cached Biology News:Ants show us how to make super-highways 2Focused ultrasound relieves fibroid symptoms in women 2First confirmed common genetic risk factors for breast cancer 2
... provide fast and reliable scalable automation for ... drug development laboratories. Staccato systems are available ... Application Series and Custom Systems Series. The ... compact system for performing ELISA assays. At ...
... researcher, the new 4300 DNA Analysis System from ... quality of your data. High confidence in more ... LI-COR DNA analysis systems have had for more ... third generation instrument based on LI-CORs highly sensitive ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
Biology Products: